Polatuzumab vedotin is a CD79b ADC for Large B-cell lymphomas (LBCL) Research
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b for Large B-cell lymphomas (LBCL) Research. CD79b is a surface antigen whose expression is restricted to pre‐B and mature B cells. Besides,…